Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $647.0 million.

  • Harmony Biosciences Holdings' Cash & Equivalents rose 5638.76% to $647.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $647.0 million, marking a year-over-year increase of 5638.76%. This contributed to the annual value of $453.0 million for FY2024, which is 2634.67% up from last year.
  • Latest data reveals that Harmony Biosciences Holdings reported Cash & Equivalents of $647.0 million as of Q3 2025, which was up 5638.76% from $546.0 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' Cash & Equivalents' 5-year high stood at $647.0 million during Q3 2025, with a 5-year trough of $141.2 million in Q1 2021.
  • Moreover, its 5-year median value for Cash & Equivalents was $324.6 million (2023), whereas its average is $335.6 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 1444.76% in 2021, then surged by 5902.85% in 2022.
  • Harmony Biosciences Holdings' Cash & Equivalents (Quarter) stood at $234.3 million in 2021, then increased by 22.43% to $286.9 million in 2022, then rose by 24.98% to $358.5 million in 2023, then grew by 26.35% to $453.0 million in 2024, then surged by 42.83% to $647.0 million in 2025.
  • Its Cash & Equivalents was $647.0 million in Q3 2025, compared to $546.0 million in Q2 2025 and $489.0 million in Q1 2025.